Clinical Trial: A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.

U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07520565) titled 'A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.' on Feb. 12.

Brief Summary: The purpose of this study was to evaluate the efficacy of early administration of BXOS110 for injection in reducing overall disability in patients with acute ischaemic stroke

Study Start Date: Jan. 19

Study Type: INTERVENTIONAL

Condition: AIS

Intervention: DRUG: BXOS110

BXOS110，Intravenous infusion administration once，3.0 mg/kg, with a maximum dose of up to 300 mg ...